These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 22706175)

  • 1. Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma.
    Richey SL; Tamboli P; Ng CS; Lin E; Lim ZD; Araujo JC; Jonasch E; Sharma P; Pagliaro LC; Tannir NM
    Am J Clin Oncol; 2013 Oct; 36(5):450-4. PubMed ID: 22706175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial.
    Treat J; Bonomi P; McCleod M; Christiansen NP; Mintzer DM; Monberg MJ; Ye Z; Chen R; Obasaju CK
    Lung Cancer; 2006 Jul; 53(1):77-83. PubMed ID: 16730854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer: a randomized phase II SICOG trial.
    Comella P; Chiuri VE; De Cataldis G; Filippelli G; Maiorino L; Vessia G; Cioffi R; Mancarella S; Putzu C; Greco E; Palmeri L; Costanzo R; Avallone A; Franco L
    Lung Cancer; 2010 Apr; 68(1):94-8. PubMed ID: 19545929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
    Tagawa ST; Milowsky MI; Jeske S; Mazumdar M; Kung S; Sung M; Lehrer D; Matulich D; Selzer J; Wright JJ; Nanus DM
    Am J Clin Oncol; 2011 Oct; 34(5):443-8. PubMed ID: 20881475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium.
    von der Maase H; Lehmann J; Gravis G; Joensuu H; Geertsen PF; Gough J; Chen G; Kania M
    Ann Oncol; 2006 Oct; 17(10):1533-8. PubMed ID: 16873433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.
    Yuan Y; Cohen DJ; Love E; Yaw M; Levinson B; Nicol SJ; Hochster HS
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):371-8. PubMed ID: 20978761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial.
    West HL; Wakelee HA; Perry MC; Belt RJ; Chen R; Obasaju C
    Ann Oncol; 2009 May; 20(5):850-6. PubMed ID: 19150937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
    Zhang X; Lu J; Xu J; Li H; Wang J; Qin Y; Ma P; Wei L; He J
    Respirology; 2013 Jan; 18(1):131-9. PubMed ID: 22882698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapy.
    Pippen J; Elias AD; Neubauer M; Stokoe C; Vaughn LG; Wang Y; Orlando M; Shonukan O; Muscato J; O'Shaughnessy JA; Gralow J
    Clin Breast Cancer; 2010 Apr; 10(2):148-53. PubMed ID: 20299319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial.
    Duruisseaux M; Baudrin L; Quoix E; Wislez M; Moro-Sibilot D; Coëtmeur D; Monnet I; Mourlanette P; Morère JF; Soria JC; Westeel V; Morin F; Cadranel J
    J Thorac Oncol; 2012 Sep; 7(9):1423-31. PubMed ID: 22767177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer.
    Dudek AZ; Larson T; McCleod MJ; Schneider DJ; Dowell JE; Banerjee TK; Pandya KJ; Bromund JL; Chen R; Monberg MJ; Obasaju CK
    J Thorac Oncol; 2008 Apr; 3(4):394-9. PubMed ID: 18379358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
    Bylicki O; Ferlay C; Chouaid C; Lavolé A; Barlési F; Dubos C; Westeel V; Créquit J; Corre R; Vergnenègre A; Monnet I; Le Caer H; Fournel P; Vaylet F; Falchero L; Poudenx M; Linard P; Pérol D; Zalcman G; Pérol M
    J Thorac Oncol; 2013 Jul; 8(7):906-14. PubMed ID: 23591160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116.
    Casey EM; Harb W; Bradford D; Bufill J; Nattam S; Patel J; Fisher W; Latz JE; Li X; Wu J; Hanna N
    J Thorac Oncol; 2010 Nov; 5(11):1815-20. PubMed ID: 20881647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer.
    Monnerat C; Le Chevalier T; Kelly K; Obasaju CK; Brahmer J; Novello S; Nakamura T; Liepa AM; Bozec L; Bunn PA; Ettinger DS
    Clin Cancer Res; 2004 Aug; 10(16):5439-46. PubMed ID: 15328182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer.
    Novarino AM; Satolli MA; Chiappino I; Giacobino A; Napoletano R; Ceccarelli M; Ciccone G; Schena M; Bertetto O; Ciuffreda L
    Am J Clin Oncol; 2013 Oct; 36(5):466-71. PubMed ID: 22781390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer.
    Ma CX; Nair S; Thomas S; Mandrekar SJ; Nikcevich DA; Rowland KM; Fitch TR; Windschitl HE; Hillman SL; Schild SE; Jett JR; Obasaju C; Adjei AA; ; ;
    J Clin Oncol; 2005 Sep; 23(25):5929-37. PubMed ID: 16135464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.
    Robert NJ; Conkling PR; O'Rourke MA; Kuefler PR; McIntyre KJ; Zhan F; Asmar L; Wang Y; Shonukan OO; O'Shaughnessy JA
    Breast Cancer Res Treat; 2011 Feb; 126(1):101-8. PubMed ID: 21188632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer.
    Fury MG; Haque S; Stambuk H; Shen R; Carlson D; Pfister D
    Cancer; 2011 Feb; 117(4):795-801. PubMed ID: 20922785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.
    Tannir NM; Thall PF; Ng CS; Wang X; Wooten L; Siefker-Radtke A; Mathew P; Pagliaro L; Wood C; Jonasch E
    J Urol; 2008 Sep; 180(3):867-72; discussion 872. PubMed ID: 18635226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung cancer.
    Spigel DR; Hainsworth JD; Barton JH; Patton JF; Zubkus JD; Simons L; Griner P; Burris HA; Greco FA
    J Thorac Oncol; 2010 Jun; 5(6):841-5. PubMed ID: 20421819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.